44 results
8-K
EX-99.1
DRRX
Durect Corp
7 Mar 19
DURECT Corporation Announces Fourth Quarter and Full Year 2018 Financial Results and Update of Programs
4:16pm
rapid enrollment of severe AH patients, and strong encouragement from several of our key expert advisors and clinical trial investigators, we have … , the relatively rapid enrollment of severe AH patients, and strong encouragement from several of our key expert advisors and clinical trial investigators, we
8-K
EX-99.1
DRRX
Durect Corp
19 Jan 10
Other Events
12:00am
was designed based on feedback from the FDA as well as input from expert consultants and key opinion leaders,” stated Joe Stauffer, Chief Medical Officer
8-K
EX-99.1
pdz7xfgn3
10 Apr 23
Company on track to report data from ongoing Phase 2b AHFIRM trial in 2H 2023
9:30am
8-K
EX-99.1
chflh9chh
2 May 18
DURECT Corporation Announces First Quarter 2018 Financial Results and Provides Corporate Update
4:15pm
PRE 14A
h2ay gotv3ma8jnw4a
15 Apr 10
Preliminary proxy
12:00am
S-1
EX-10.10
p4527 bhp
20 Apr 00
IPO registration
12:00am